Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CNCE

Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis

Concert Pharmaceuticals logo

About Concert Pharmaceuticals Stock (NASDAQ:CNCE)

Key Stats

Today's Range
$8.37
$8.37
50-Day Range
$8.33
$8.40
52-Week Range
$2.66
$8.55
Volume
N/A
Average Volume
2.97 million shs
Market Capitalization
$401.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

How Low-Cost Stocks Generate Monthly Income
Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!
See More Headlines

CNCE Stock Analysis - Frequently Asked Questions

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.03. The biotechnology company earned $0.54 million during the quarter, compared to analyst estimates of $0.25 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Concert Pharmaceuticals investors own include Intel (INTC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Global Blood Therapeutics (GBT), Micron Technology (MU), Pfizer (PFE) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/09/2021
Today
12/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Profitability

Net Income
$-80,050,000.00
Pretax Margin
-300,735.69%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Book Value
$3.24 per share

Miscellaneous

Free Float
42,507,000
Market Cap
$401.26 million
Optionable
Optionable
Beta
0.52

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CNCE) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners